Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diabetes

  Free Subscription

Articles published in
Lancet
    July 2021
  1. TEUFEL F, Seiglie JA, Geldsetzer P, Theilmann M, et al
    Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults.
    Lancet. 2021;398:238-248.
    >> Share

  2. CHOUKEM SP, Dimala CA
    BMI and diabetes risk in low-income and middle-income countries.
    Lancet. 2021;398:190-192.
    >> Share

  3. BROWN E, Heerspink HJL, Cuthbertson DJ, Wilding JPH, et al
    SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Lancet. 2021;398:262-276.
    >> Share

  4. NAZZAL Z, Khatib B, Al-Quqa B, Abu-Taha L, et al
    The prevalence and risk factors of urinary incontinence among women with type 2 diabetes in the north West Bank: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S42.
    >> Share

  5. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    >> Share

  6. ATALLAH SM, Al-Jaghbir MT, Zayed AA
    The prevalence of diabetic peripheral neuropathy among diabetic Palestinian refugees in the Nuzha area, Jordan: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S15.
    >> Share

    June 2021
  7. TAN TM, Khoo B
    Tirzepatide and the new era of twincretins for diabetes.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01390.
    >> Share

  8. ROSENSTOCK J, Wysham C, Frias JP, Kaneko S, et al
    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01324.
    >> Share

  9. CHAN JCN, Lim LL, Shaw JE, Aguilar-Salinas CA, et al
    Data on diabetes-specific distress are needed to improve the quality of diabetes care - Authors' reply.
    Lancet. 2021;397:2150.
    >> Share

  10. SPEIGHT J, Hermanns N, Ehrmann D
    Data on diabetes-specific distress are needed to improve the quality of diabetes care.
    Lancet. 2021;397:2149.
    >> Share

  11. ARNETT DK
    Widespread diabetes screening for cardiovascular disease risk estimation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)00764.
    >> Share

  12. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)00572.
    >> Share

  13. VISSER MM, Charleer S, Fieuws S, De Block C, et al
    Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)00789.
    >> Share

    May 2021
  14. SYN NL, Cummings DE, Wang LZ, Lin DJ, et al
    Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.
    Lancet. 2021 May 6. pii: S0140-6736(21)00591.
    >> Share

    April 2021
  15. MIZELLE RM JR
    Diabetes, race, and amputations.
    Lancet. 2021;397:1256-1257.
    >> Share

    March 2021
  16. DEVI S
    Aid agencies turn attention to diabetes.
    Lancet. 2021;397:1049-1050.
    >> Share

  17. LATINI R, Staszewsky L
    Semaglutide and effective weight control.
    Lancet. 2021;397:942-943.
    >> Share

  18. DAVIES M, Faerch L, Jeppesen OK, Pakseresht A, et al
    Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Lancet. 2021 Mar 2. pii: S0140-6736(21)00213.
    >> Share

    January 2021
  19. MINGRONE G, Panunzi S, De Gaetano A, Guidone C, et al
    Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.
    Lancet. 2021;397:293-304.
    >> Share

  20. MIRAS AD, le Roux CW
    Metabolic surgery versus conventional therapy in type 2 diabetes.
    Lancet. 2021;397:256-257.
    >> Share

  21. BERGENSTAL RM, Nimri R, Beck RW, Criego A, et al
    A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
    Lancet. 2021;397:208-219.
    >> Share

    December 2020
  22. THOMPSON KM
    Poliovirus vaccine options: another step forward.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32629.
    >> Share

    November 2020
  23. ZACCARDI F, Khunti K, Marx N, Davies MJ, et al
    First-line treatment for type 2 diabetes: is it too early to abandon metformin?
    Lancet. 2020;396:1705-1707.
    >> Share

  24. THE LANCET
    Turning evidence into action on diabetes.
    Lancet. 2020;396:1535.
    >> Share

  25. CHAN JCN, Lim LL, Wareham NJ, Shaw JE, et al
    The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32374.
    >> Share

  26. DAIN K
    Data-driven policies needed to turn the tide on diabetes.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32378.
    >> Share

  27. WATTS G
    Rury Holman: the science of diabetes and a life of trials.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32380.
    >> Share

    September 2020

  28. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4.
    Lancet. 2020;396:918-934.
    >> Share

  29. BOXHOORN L, Voermans RP, Bouwense SA, Bruno MJ, et al
    Acute pancreatitis.
    Lancet. 2020;396:726-734.
    >> Share

    August 2020
  30. ZANNAD F, Ferreira JP, Pocock SJ, Anker SD, et al
    SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31824.
    >> Share

    July 2020
  31. BHATT DL, Steg PG
    Differential effect of ticagrelor on irreversible harms in diabetes - Authors' reply.
    Lancet. 2020;396:93-94.
    >> Share

  32. CHI G, Marszalek J
    Differential effect of ticagrelor on irreversible harms in diabetes.
    Lancet. 2020;396:93.
    >> Share

  33. REGAN J
    Collaborating on kidneys: Haiti's transplantation ambitions.
    Lancet. 2020;396:15-16.
    >> Share

    March 2020
  34. ZHOU F, Yu T, Du R, Fan G, et al
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Lancet. 2020 Mar 11. pii: S0140-6736(20)30566.
    >> Share

    February 2020

  35. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.
    Lancet. 2020;395:698-708.
    >> Share

  36. OLIVA-DAMASO N, Oliva-Damaso E, Payan J, Porrini E, et al
    Dulaglutide slows kidney disease in type 2 diabetes.
    Lancet. 2020;395:559.
    >> Share

  37. GERSTEIN HC
    Dulaglutide slows kidney disease in type 2 diabetes - Author's reply.
    Lancet. 2020;395:559-560.
    >> Share


  38. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2020 Feb 13. pii: S0140-6736(20)30045.
    >> Share

    January 2020
  39. HEERSPINK HJL, Parving HH, de Zeeuw D
    Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply.
    Lancet. 2020;395:270.
    >> Share

  40. SEPE V, Libetta C
    Atrasentan in patients with diabetes and chronic kidney disease.
    Lancet. 2020;395:269.
    >> Share

  41. LIU D, Liu Z
    Atrasentan in patients with diabetes and chronic kidney disease.
    Lancet. 2020;395:269-270.
    >> Share

  42. HEIDA JE, Gansevoort RT, van Beek AP
    Use of copeptin in the diagnosis of polyuria-polydipsia syndrome.
    Lancet. 2020;395:267.
    >> Share

  43. GARRETT C, Ismail K
    Forgotten: mental health interventions in type 1 diabetes.
    Lancet. 2020;395:115.
    >> Share

    October 2019
  44. BERGENSTAL RM, Johnson ML, Bashan E, Hodish I, et al
    Insulin dosing guidance to optimise type 2 diabetes management - Authors' reply.
    Lancet. 2019;394:1321.
    >> Share

  45. GARG R
    Insulin dosing guidance to optimise type 2 diabetes management.
    Lancet. 2019;394:1320-1321.
    >> Share

    September 2019
  46. MOSENZON O, Leibowitz G
    VERIFY the role of initial combination therapy in patients with type 2 diabetes.
    Lancet. 2019 Sep 17. pii: S0140-6736(19)32165.
    >> Share

  47. MATTHEWS DR, Paldanius PM, Proot P, Chiang Y, et al
    Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Lancet. 2019 Sep 17. pii: S0140-6736(19)32131.
    >> Share

  48. BECK RW, Bergenstal RM, Laffel LM, Pickup JC, et al
    Advances in technology for management of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31142.
    >> Share

  49. DAYAN CM, Korah M, Tatovic D, Bundy BN, et al
    Changing the landscape for type 1 diabetes: the first step to prevention.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)32127.
    >> Share

  50. VANTYGHEM MC, de Koning EJP, Pattou F, Rickels MR, et al
    Advances in beta-cell replacement therapy for the treatment of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31334.
    >> Share

    August 2019
  51. VALGIMIGLI M, Manavifar N
    Ticagrelor in patients with diabetes and previous PCI.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31957.
    >> Share

  52. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    >> Share

  53. ROSHANDEL G, Khoshnia M, Poustchi H, Hemming K, et al
    Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet. 2019;394:672-683.
    >> Share

  54. ZELNIKER TA, Wiviott SD, Raz I, Sabatine MS, et al
    SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.
    Lancet. 2019;394:560-561.
    >> Share

  55. STRANDBERG TE, Petrovic M, Benetos A
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:560.
    >> Share

  56. MALAGA G, Ruiz EF
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:559-560.
    >> Share

  57. BARNETT R
    Type 2 diabetes.
    Lancet. 2019;394:557.
    >> Share

  58. HOORN EJ
    Testing the waters: a new test for hypotonic polyuria.
    Lancet. 2019;394:546-547.
    >> Share

  59. LEVAILLANT M, Lievre G, Baert G
    Ending diabetes in Mexico.
    Lancet. 2019;394:467-468.
    >> Share

    July 2019
  60. WINZELER B, Cesana-Nigro N, Refardt J, Vogt DR, et al
    Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study.
    Lancet. 2019 Jul 11. pii: S0140-6736(19)31255.
    >> Share

  61. HOLST JJ
    Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
    Lancet. 2019;394:4-6.
    >> Share

    June 2019
  62. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    >> Share

  63. VERMA S, Mazer CD, Perkovic V
    Is it time to REWIND the cardiorenal clock in diabetes?
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31267.
    >> Share

  64. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31150.
    >> Share

  65. PRATLEY R, Amod A, Hoff ST, Kadowaki T, et al
    Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31271.
    >> Share

    May 2019
  66. LUO J, Gonsalves G, Greene J
    Insulin for all: treatment activism and the global diabetes crisis.
    Lancet. 2019;393:2116-2117.
    >> Share

  67. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    >> Share

  68. GREGG EW, Cheng Y, Imperatore G
    Trend analysis of diabetic mortality - Authors' reply.
    Lancet. 2019;393:1932.
    >> Share

  69. YUAN X, Song F, Zhang L
    Trend analysis of diabetic mortality.
    Lancet. 2019;393:1931-1932.
    >> Share

  70. WATTS G
    Shitaye Alemu Balcha: committed to rural health care in Ethiopia.
    Lancet. 2019;393:1797.
    >> Share

    April 2019
  71. ZHONG D, Yi Y, Lin C
    A kidney changes size: first increasing and then decreasing.
    Lancet. 2019;393:1641.
    >> Share

  72. TUTTLE KR
    A turning point for chronic kidney disease in diabetes.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30855.
    >> Share

  73. HEERSPINK HJL, Parving HH, Andress DL, Bakris G, et al
    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30772.
    >> Share

    March 2019
  74. THE LANCET
    Gestational diabetes in England: cause for concern.
    Lancet. 2019;393:1262.
    >> Share

  75. EVANS ML, Golubic R
    Technology to overcome clinical inertia in insulin therapy.
    Lancet. 2019;393:1078-1080.
    >> Share

  76. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    >> Share

  77. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    >> Share

  78. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    >> Share

  79. XIAO F, Liu M, Wang XF
    Involuntary choreiform movements in a diabetic patient.
    Lancet. 2019;393:1033.
    >> Share

    February 2019
  80. BERGENSTAL RM, Johnson M, Passi R, Bhargava A, et al
    Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
    Lancet. 2019 Feb 22. pii: S0140-6736(19)30368.
    >> Share

    January 2019
  81. STEDMAN M, Lunt M, Livingston M, Fryer AA, et al
    The costs of drug prescriptions for diabetes in the NHS.
    Lancet. 2019;393:226-227.
    >> Share

  82. THE LANCET
    Modernising the NHS: leading the way with diabetes.
    Lancet. 2019;393:200.
    >> Share

  83. VERMA S, Juni P, Mazer CD
    Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
    Lancet. 2019;393:3-5.
    >> Share

    December 2018
  84. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    >> Share

  85. THE LANCET
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.
    >> Share

    November 2018
  86. UNAMUNO X, Fruhbeck G
    Lorcaserin: balancing efficacy with potential risks.
    Lancet. 2018;392:2239-2240.
    >> Share

  87. STUMVOLL M, Tschop M
    Twice the benefits with twincretins?
    Lancet. 2018;392:2142-2144.
    >> Share

  88. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    >> Share

    October 2018
  89. TAYLOR R, Adamson AJ, Sattar N, Lean MEJ, et al
    VLCD for weight loss and remission of type 2 diabetes? - Authors' reply.
    Lancet. 2018;392:1307.
    >> Share

  90. AHMAD N, Alfaris N
    VLCD for weight loss and remission of type 2 diabetes?
    Lancet. 2018;392:1306-1307.
    >> Share

  91. BOHULA EA, Scirica BM, Inzucchi SE, McGuire DK, et al
    Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32328.
    >> Share

  92. FRIAS JP, Nauck MA, Van J, Kutner ME, et al
    Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32260.
    >> Share

  93. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
    >> Share

  94. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    >> Share

  95. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    >> Share

  96. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    >> Share

    September 2018

  97. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4.
    Lancet. 2018;392:1072-1088.
    >> Share

    August 2018
  98. KLUGER AY, McCullough PA
    Semaglutide and GLP-1 analogues as weight-loss agents.
    Lancet. 2018;392:615-616.
    >> Share

  99. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    >> Share

  100. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    >> Share

  101. MCCALL C
    Biosimilars for insulin: a cost-saving alternative?
    Lancet. 2018;392:463-464.
    >> Share

    July 2018
  102. PALMER SC, Strippoli GFM
    Metformin as first-line treatment for type 2 diabetes.
    Lancet. 2018;392:120.
    >> Share

    June 2018
  103. RAYNER CK, Horowitz M
    Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30936.
    >> Share

  104. AMBERY P, Parker VE, Stumvoll M, Posch MG, et al
    MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30726.
    >> Share

  105. LANGENBERG C, Lotta LA
    Genomic insights into the causes of type 2 diabetes.
    Lancet. 2018;391:2463-2474.
    >> Share

  106. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    >> Share

  107. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    >> Share

  108. STEYN M, Couchman L, Coombes G, Earle KA, et al
    A herbal treatment for type 2 diabetes adulterated with undisclosed drugs.
    Lancet. 2018;391:2411.
    >> Share

  109. THE LANCET
    Untangling the complications of diabetes.
    Lancet. 2018;391:2389.
    >> Share

    May 2018
  110. BENNETT PH
    Diabetes mortality in the USA: winning the battle but not the war?
    Lancet. 2018 May 18. pii: S0140-6736(18)30843.
    >> Share

  111. GREGG EW, Cheng YJ, Srinivasan M, Lin J, et al
    Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.
    Lancet. 2018 May 18. pii: S0140-6736(18)30314.
    >> Share

    March 2018
  112. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    >> Share

  113. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    >> Share

  114. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    >> Share

    February 2018
  115. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    >> Share

  116. SARHAN MB, Ghandour R, Rmeileh NMEA
    The effectiveness of counselling interventions in reducing HbA1c concentrations in patients with type 2 diabetes: a modelling study.
    Lancet. 2018;391 Suppl 2:S30.
    >> Share

  117. SAMAN KA, Massad S, Ibaid AA, Anan H, et al
    Factors associated with depression in patients with type 2 diabetes in the Gaza Strip: a cross sectional study.
    Lancet. 2018;391 Suppl 2:S19.
    >> Share

  118. CANALI G, Tittle V, Seita A
    Medication adherence by Palestine refugees living in Jordan who have diabetes: a cross-sectional study.
    Lancet. 2018;391 Suppl 2:S13.
    >> Share

  119. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    >> Share

  120. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    >> Share

    January 2018
  121. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    >> Share

    December 2017
  122. UUSITUPA M
    Remission of type 2 diabetes: mission not impossible.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33100.
    >> Share

  123. LEAN ME, Leslie WS, Barnes AC, Brosnahan N, et al
    Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33102.
    >> Share

    November 2017
  124. BROWN DM, Wykoff CC
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2141.
    >> Share

  125. SIVAPRASAD S, Prevost AT, Vasconcelos J, Riddell A, et al
    Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.
    Lancet. 2017;390:2141-2142.
    >> Share

  126. LIU L, Tham YC, Cheng CY
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2140-2141.
    >> Share

    October 2017
  127. MCGAVOCK J, Wicklow B, Dart AB
    Type 2 diabetes in youth is a disease of poverty.
    Lancet. 2017;390:1829.
    >> Share

    September 2017
  128. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    >> Share

  129. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    >> Share

  130. JEFFCOATE W, Barron E, Lomas J, Valabhji J, et al
    Using data to tackle the burden of amputation in diabetes.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32401.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016